SEC Form 4 · accession 0001179110-17-003116
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Feb 22, 2017
Accepted (ET)
Feb 24, 2017 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $12.07 | Feb 22, 2017 | A | 251,923 | A | Feb 22, 2018 | Feb 22, 2027 | Common Stock | 251,923 | 251,923 | D |
| Restricted Stock UnitsF2 | $0.00 | Feb 22, 2017 | A | 157,416 | A | Feb 22, 2018 | — | Common Stock | 157,416 | 157,416 | D |
Explanation of responses
- F1This option vests one-fourth on such date and then 1/48th monthly thereafter.
- F2This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.